C

Cencora

Distributes medicines and supports patient care

National Customer Service Manager

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Seoul, South Korea
In Person
Operations & LogisticsLogistics & Transportation

About the job

Requirements
  • Experienced people management is required.
  • International experience, such as experience in a multinational corporation or overseas study, is required.
  • Experience in a similar role is required.
  • Ability to analyze situations systematically, critically evaluate numerical and narrative information, and draw accurate conclusions.
  • Ability to respond positively to change and remain effective amid new situations, uncertainty, and ambiguity.
  • Ability to generate creative ideas and resourceful approaches to problems.
  • Ability to make timely, appropriate decisions based on analysis and experience, exercise sound judgment under uncertainty, anticipate decision impacts, and plan to manage risk.
  • Ability to plan and organize work toward high-priority goals, monitor progress, anticipate problems, revise plans, schedule time effectively, and use efficient methods and tools.
  • Ability to achieve critical tasks and measurable results, overcome obstacles, adjust approaches, and focus self and others on targets aligned with business goals.
  • Ability to work cooperatively to achieve targets, support team goals and group decisions, and offer help to colleagues.
  • Ability to act responsibly, keep commitments, comply with policies and agreements, and build trust through professionalism, integrity, expertise, and results.
  • Ability to challenge self and others to exceed standards and persist through obstacles or delays.
  • Ability to provide timely, clear, and concise verbal and written information, adapt communication to others, listen attentively, and clarify information as needed.
  • Ability to remain calm, objective, and controlled in urgent or demanding situations and maintain effective performance under pressure.
  • Thorough knowledge of the international airfreight industry.
  • Comprehensive understanding of government legislative requirements.
  • Proficiency with information technology.
Responsibilities
  • Identify and implement processes and training that improve service outcomes.
  • Maintain and develop performance standards and customer outcomes.
  • Review and ensure that Operations and Customer Service work efficiently.
  • Ensure internal and external communications are accurate, consistent, timely, and concise.
  • Develop industry relationships to establish optimal shipment transits, including cargo recovery, lodgement, and clearance.
  • Take pre-emptive and proactive action to prevent service-delivery problems.
  • Monitor and measure service quality across systems, staff, and carriers.
  • Create and implement strategies and plans to develop staff capabilities.
  • Review and adapt the organizational structure to align with development.
  • Monitor and develop the network to ensure service delivery.
  • Directly or indirectly supervise operations staff.
  • Develop and maintain staff skill levels through an annual training program.
  • Develop and maintain staff cross-training and multitasking programs.
  • Keep staff informed about Operations policies, procedures, guidelines, regulatory compliance, and relevant information technology hardware and software developments.
  • Work with the Information Technology area to ensure office systems and support services are operational and effectively support the business.
  • Liaise with the Information Technology area to represent Operations' interests and provide feedback.
  • Induct new staff on their responsibilities and the requirements and expectations of World Courier.
  • Monitor and review staff key performance indicators.
  • Conduct performance appraisals for all direct reports at least every six months, and more often if required.
  • Identify, nurture, and develop strong performers.
  • Address poor performance through training, supervision, feedback, and coaching.
  • Obtain General Manager approval before dismissing or managing out a staff member.
  • Ensure Unfair Dismissal Act requirements are met when dismissal is necessary.
  • Monitor and ensure secure, speedy, and innovative routings are used.
  • Lead or oversee negotiations of contracts and rates with agents and carriers.
  • Ensure arrangements with airlines, ground handlers, and routings are efficient and cost-effective.
  • Stay informed about and comply with government legislative and other requirements, including applicable inspection and quarantine, food and drug authority, health ministry, International Air Transport Association, and International Organization for Standardization requirements.
  • Prepare an annual Operations Plan for the General Manager outlining proposed initiatives, activities, and developments.
  • Prepare a monthly operations report and a six-month overview for the General Manager.
  • Complete internal reporting to Head Office standards and by the due date.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.